LifeVantage disclosed that a laboratory study performed on cultured gut cells found its proprietary P84 blend increased the expression and secretion of 14 key gut peptides, including CCK, NTS, EREG, GRP, OXM, CDH1, TFF3, Zonulin, CLDN1, OCLN, MUC2, GLP‑2, VIP, and SST. The work was conducted in a controlled, third‑party setting and is the first step toward evaluating P84’s potential in humans.
The data show dramatic percentage increases for several peptides: GRP rose by 1,087%, TFF3 by 116%, VIP by 100%, OXM by 77%, and CCK by 69%. Across the panel, P84 exceeded typical biomarker thresholds of 20‑30%, indicating a robust cellular response that could translate into measurable gut‑health benefits once clinical studies are completed.
The study follows LifeVantage’s October 2025 acquisition of LoveBiome, a company that specializes in microbiome‑based nutraceuticals. The acquisition expands LifeVantage’s gut‑health portfolio and positions the firm to capitalize on a market projected to grow from $14.4 billion in 2025 to $32.4 billion by 2035. By integrating P84 with LoveBiome’s expertise, LifeVantage aims to create a differentiated product line that leverages both peptide activation and microbiome modulation.
In its most recent earnings, LifeVantage reported revenue of $47.6 million for the quarter ended September 30, 2025, a 0.7% year‑over‑year increase that fell short of analyst expectations of $54.75 million. Net income rose to $2.2 million, and earnings per share of $0.17 beat the consensus of $0.20, a $0.03 or 15% beat. The modest revenue miss was largely driven by a 1.5% decline in legacy product sales, offset by a 3% gain in the new nutrigenomic segment. The EPS beat was attributed to disciplined cost management and a favorable mix shift toward higher‑margin products.
Investors have approached the announcement with caution, citing the company’s recent revenue misses and the volatility of its share price. While the in‑vitro findings are promising, the lack of clinical data means the results cannot yet be translated into marketable claims or regulatory approvals. The market’s tempered reaction reflects the need for further evidence before the study can influence consumer demand or investor sentiment.
CEO Steve Fife emphasized that the LoveBiome acquisition and the P84 study are “pivotal milestones” that reinforce LifeVantage’s focus on GLP‑1 activation and microbiome health. Vice President of R&D Lisa Barnes highlighted the “remarkable impact” of P84 on cellular pathways, noting that the peptide activation profile aligns with the company’s long‑term strategy to develop nutrigenomic products that modulate gut‑brain signaling.
Looking ahead, LifeVantage plans to combine P84 with its Protandim Nrf2 Synergizer and MindBody GLP‑1 System in future research. The company believes that integrating these platforms could unlock new revenue streams in the expanding gut‑health supplement market and accelerate the commercialization of a next‑generation nutraceutical portfolio.
The in‑vitro study represents a significant step in LifeVantage’s quest to deliver science‑backed gut‑health solutions. By demonstrating robust peptide activation, the company has laid the groundwork for future clinical studies that could validate the therapeutic potential of P84 and solidify its position in a rapidly growing market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.